TABLE 3.
Comparison of red cell indices of the alectinib‐treated patients versus crizotinib‐treated patients or lorlatinib‐treated patients.
| Alectinib (mean) | Crizotinib (mean) | p value | Lorlatinib (mean) | p value | |
|---|---|---|---|---|---|
| Hb (g/dL) | 11.4 | 13.2 | <0.001 | 13.5 | <0.001 |
| MCV (fL) | 86.0 | 92.3 | 0.002 | 87.2 | 0.538 |
| MCH (pg) | 29.4 | 31.3 | 0.005 | 28.7 | 0.339 |
| MCHC (g/dL) | 34.2 | 33.4 | 0.008 | 32.9 | <0.001 |
| RBC (×1012/L) | 3.90 | 4.30 | 0.031 | 4.74 | 0.001 |
| HCT | 0.332 | 0.396 | <0.001 | 0.412 | <0.001 |
| RDW | 14.7 | 13.0 | 0.002 | 13.7 | 0.089 |
| Reticulocyte count | 2.34% | 1.90% | 0.039 | 1.59% | <0.001 |
Note: p values which are <0.05 are bolded.
Abbreviations: Hb, haemoglobin concertation; HCT, haematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin concentration; RBC, red blood cell count; RDW, red cell distribution width.